Regulation of VEGFA, KRAS, and NFE2L2 Oncogenes by MicroRNAs in Head and Neck Cancer
Authors:
- Caroline Izak CuzziolCCCaroline Izak Cuzziol
- Ludimila Leite MarzochiLMLudimila Leite Marzochi
- Vitória Scavacini PossebonVPVitória Scavacini Possebon
- Rosa Sayoko Kawasaki-OyamaRKRosa Sayoko Kawasaki-Oyama
- Marlon Fraga MattosMMMarlon Fraga Mattos
- Vilson Serafim JuniorVJVilson Serafim Junior
- Letícia Antunes Muniz FerreiraLFLetícia Antunes Muniz Ferreira
- Érika Cristina PavarinoÉPÉrika Cristina Pavarino
- Márcia Maria Urbanin Castanhole-NunesMCMárcia Maria Urbanin Castanhole-Nunes
- Eny Maria Goloni-BertolloEGEny Maria Goloni-Bertollo
Open Access
- 5 July 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (13) , 7483
Abstract
Mutations and alterations in the expression of VEGFA, KRAS, and NFE2L2 oncogenes play a key role in cancer initiation and progression. These genes are enrolled not only in cell proliferation control, but also in angiogenesis, drug resistance, metastasis, and survival of tumor cells. MicroRNAs (miRNAs) are small, non-coding regulatory RNA molecules that can regulate post-transcriptional expression of multiple target genes. We aimed to investigate if miRNAs hsa-miR-17-5p, hsa-miR-140-5p, and hsa-miR-874-3p could interfere in VEGFA, KRAS, and NFE2L2 expression in cell lines derived from head and neck cancer (HNC). FADU (pharyngeal cancer) and HN13 (oral cavity cancer) cell lines were transfected with miR-17-5p, miR-140-5p, and miR-874-3p microRNA mimics. RNA and protein expression analyses revealed that miR-17-5p, miR-140-5p and miR-874-3p overexpression led to a downregulation of VEGFA, KRAS, and NFE2L2 gene expression in both cell lines analyzed. Taken together, our results provide evidence for the establishment of new biomarkers in the diagnosis and treatment of HNC.Keywords
Funding Information
- São Paulo Research Foundation (2018/26166-6, 2020/03209-1, 2015/04403-8, 001, 310987/2018-0)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (2018/26166-6, 2020/03209-1, 2015/04403-8, 001, 310987/2018-0)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (2018/26166-6, 2020/03209-1, 2015/04403-8, 001, 310987/2018-0)
This publication has 53 references indexed in Scilit:
- Head and Neck Cancer: Underfunded and Understudied?Otolaryngology–Head and Neck Surgery, 2016
- The Dual Roles of NRF2 in CancerTrends in Molecular Medicine, 2016
- MicroRNA Therapeutics: the Next Magic Bullet?Mini-Reviews in Medicinal Chemistry, 2015
- MicroRNAs in CancerAnnual Review of Pathology: Mechanisms of Disease, 2014
- Underexpression of miR-34a in Hepatocellular Carcinoma and Its Contribution towards Enhancement of Proliferating Inhibitory Effects of Agents Targeting c-METPLOS ONE, 2013
- MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinomaHepatology, 2013
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesisNature, 2011
- NRF2 Blockade Suppresses Colon Tumor Angiogenesis by Inhibiting Hypoxia-Induced Activation of HIF-1αCancer Research, 2011
- NAViGaTing the Micronome – Using Multiple MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAsPLOS ONE, 2011
- Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate CancerCancer Research, 2008